A groundbreaking study led by the Berman Lab at the CHEO Research Institute and the University of Ottawa, in close collaboration with national precision oncology networks across Canada and Australia, has demonstrated the power of pre-clinical zebrafish models in real-time clinical decision-making. This research marks a pivotal step forward by establishing that larval zebrafish patient-derived xenograft (PDX) models can reliably replicate and predict drug responses observed in actual pediatric cancer patients. Unlike traditional mouse models, which have dominated the pre-clinical landscape, zebrafish offer unparalleled speed, cost-effectiveness, and sensitivity that could revolutionize precision pediatric oncology.

Dr. Jason Berman, pediatric oncologist and CEO of CHEO Research Institute, underscores the personal impact of this innovation. “When delivering difficult news to families, having the ability to offer hope based on a concrete understanding of how a child might respond to treatment is invaluable,” he explains. Zebrafish offer that window into personalized therapy, illuminating effective drug regimens well ahead of conventional models. Their unique biology—small size, rapid development, and optical transparency—enables researchers to graft human tumor tissues and observe therapeutic effects in a live organism within days, vastly accelerating the treatment selection process.

In terms of technical specifics, the larval zebrafish PDX approach involves transplanting tumor cells derived from pediatric patients directly into transparent larvae. These xenografts allow for direct observation of tumor drug responses in real-time, facilitating precise evaluation of efficacy and resistance patterns. This approach is particularly advantageous in pediatric oncology, where sample sizes from biopsies are limited, and treatment windows are narrow. Zebrafish models require only minute quantities of tumor tissue, a remarkable advantage over mouse models that often demand larger samples and longer engraftment periods.

The study published in Cancer Research Communications represents the first direct comparison between zebrafish PDX models, traditional mouse PDX models, and actual patient clinical outcomes. By retrospectively analyzing samples from ten children enrolled in the Zero Childhood Cancer program in Australia, researchers were able to assess the fidelity of zebrafish drug response patterns against the backdrop of real-world therapeutic results. Remarkably, the zebrafish PDX models predicted responses accurately in 11 out of 12 treatment regimens, surpassing mouse models in terms of speed and, in several cases, feasibility.

Significantly, for three of the high-risk patients whose tumor tissues failed to establish viable mouse PDX models, zebrafish larvae successfully generated robust drug response data. This finding highlights the zebrafish model’s superior adaptability and its potential to fill critical gaps in pediatric cancer research, especially for aggressive cancers where time-sensitive treatment decisions are paramount. By delivering reliable predictions in a fraction of the time, zebrafish models could effectively serve as frontline bioassays guiding personalized therapies in clinical settings.

The implications of this study stretch beyond model validation, touching on the broader paradigm of precision medicine for childhood cancers. Dr. David Malkin, co-chair of ACCESS and senior staff oncologist at SickKids, elaborates on this bridge between bench and bedside. “Precision tumor modeling with zebrafish is not merely an experimental tool; it’s a transformative clinical instrument that ensures children receive not just care, but the right care, tuned finely to their cancer’s unique biology.” Such advances are crucial because even with extensive genomic sequencing, many pediatric cancers remain without identifiable druggable mutations, leaving clinicians with few targeted treatment strategies.

Technically and ethically, zebrafish offer additional advantages that augment their value in preclinical oncology. Their rapid breeding cycles and transparent embryos permit high-throughput drug screening while minimizing ethical concerns associated with mammalian testing. The external development of embryos allows continuous real-time visualization without invasive procedures, providing unparalleled access to tumor microenvironment dynamics and drug interactions within the living organism. This system empowers researchers to iterate therapeutic testing quickly and identify promising drug candidates or combinations before advancing to more resource-intensive mammalian models or clinical trials.

Another key dimension of this research is its alignment with international collaborative networks such as Canada’s PROFYLE and Australia’s ZERO programs. These networks emphasize molecular profiling and precision medicine tailored to children and young adults with cancer, leveraging multi-institutional expertise and data-sharing. The integration of zebrafish PDX modeling with extensive genomic analyses promises a holistic approach, combining molecular insights with functional testing to optimize treatment plans. This convergence of technologies accelerates personalized therapy pipelines with the overarching goal of improving survival and quality of life for patients facing otherwise grim prognoses.

Importantly, co-senior author Dr. Michelle Haber from the Children’s Cancer Institute in Sydney highlights the clinical utility of zebrafish PDX modeling in cases where molecular profiling alone falls short. She points out that when actionable genomic targets cannot be identified, observing how patient-derived tumors respond dynamically to available drugs in zebrafish becomes a valuable alternative to guide therapeutic decisions. This innovation enhances the traditional precision medicine toolkit, ensuring more children receive hope and tailored care even in challenging diagnostic scenarios.

Beyond treatment selection, this study sets the stage for future prospective use of zebrafish models in clinical oncology. By embedding functional assays within clinical workflows, physicians could potentially receive timely, empirically supported guidance to adjust therapeutic regimens on the fly, responding to tumor evolutions and resistance mechanisms as they arise. The rapid turnaround offered by zebrafish PDX allows for such nimble clinical adaptations, potentially reducing trial-and-error approaches and sparing patients from ineffective treatments and attendant toxicities.

As the landscape of pediatric cancer therapy evolves, the promise of zebrafish models encapsulates a broader shift toward adaptive, precise, and patient-centered oncology. This model system’s success illustrates an elegant marriage of basic science and translational medicine, where organismal biology informs human healthcare. Energetic ongoing collaborations across borders exemplify the commitment to leverage these insights for tangible patient benefit, accelerating not just the pace of research but the very hope entrusted to families confronting pediatric cancer.

In sum, the zebrafish larval PDX model heralds a transformative advance in pediatric cancer precision therapy. Through its rapid, accurate, and scalable drug response profiling, it addresses crucial limitations of existing preclinical models, enabling clinicians to craft personalized therapeutic strategies with greater confidence and speed. The impact of this innovation will ripple through research, clinical protocols, and ultimately patient outcomes—offering a beacon of hope for children with some of the most aggressive and difficult-to-treat cancers.

Subject of Research: Human tissue samples

Article Title: Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy

News Publication Date: 25-Jul-2025

Web References:

• CHEO Research Institute: https://www.cheoresearch.ca/
• ACCESS: https://www.accessforkidscancer.ca/
• PROFYLE: https://www.profyle.ca/
• ZERO: https://www.zerochildhoodcancer.org.au/
• Children’s Cancer Institute: http://ccia.org.au

References:
Azzam, N., Fletcher, J. I., Melong, N., Lau, L. M. S., Dolman, E. M., Mao, J., Tax, G., Cadiz, R., Tuzi, L., Kamili, A., Dumevska, B., Xie, J., Chan, J. A., Senger, D. L., Grover, S. A., Malkin, D., Haber, M., & Berman, J. N. (2025). Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy. Cancer Research Communications, 5(7), 1215–1227. DOI: 10.1158/2767-9764.CRC-25-0080

Image Credits: CHEO

Neuroblastoma predominantly affects infants and young children and is notorious for its aggressive behavior and poor prognosis, especially in cases where the disease has metastasized. Conventional treatment regimens encompass an aggressive combination of surgery, chemotherapy, radiation, and immunotherapy. While these modalities have benefited some patients, those with metastatic disease frequently encounter treatment resistance and relapse. Moreover, survivors of neuroblastoma often endure severe long-term cognitive deficits due to the toxicity of current therapies, underscoring the urgent necessity for more targeted, less harmful interventions.

Differentiation therapy has emerged as an appealing conceptual framework in the fight against neuroblastoma. The therapeutic goal is to induce malignant cells to exit their proliferative, undifferentiated state and instead mature into non-proliferative, functionally specialized cells. Retinoic acid, a derivative of vitamin A, has been the mainstay differentiation agent used clinically; however, its effectiveness is limited by variable patient response rates and the common development of resistance during treatment. This clinical challenge has galvanized efforts to identify alternative molecular targets capable of steering neuroblastoma cells toward benign differentiation.

The Swedish research team turned their attention to two antioxidant enzymes, PRDX6 (Peroxiredoxin 6) and GSTP1 (Glutathione S-transferase Pi 1), both of which play pivotal roles in cellular redox homeostasis within cancer cells. Neuroblastoma cells are characterized by elevated oxidative stress due to their high metabolic activity, leading to an increased dependence on antioxidant systems to neutralize reactive oxygen species (ROS) and prevent apoptotic cell death. Elevated expression of PRDX6 and GSTP1 correlates with more aggressive disease and worse patient outcomes, suggesting that these enzymes are instrumental in cancer cell survival and proliferation.

Through meticulous in vitro experiments and rigorous in vivo studies using mouse models, the researchers demonstrated that dual inhibition of PRDX6 and GSTP1 not only induces selective death in a subset of neuroblastoma cells but also prompts a considerable fraction of surviving cells to differentiate into mature neurons. This phenotypic conversion effectively stymies tumor expansion by depleting the pool of undifferentiated, malignant cells. Importantly, the differentiated neurons exhibited functional characteristics akin to healthy nerve cells, indicating a functional reprogramming rather than mere phenotypic mimicry.

The mechanistic underpinnings of this differentiation induction appear to hinge on disrupting the antioxidant defenses that cancer cells exploit to maintain their malignant state. By pharmacologically inhibiting PRDX6 and GSTP1, the elevated oxidative stress surpasses a critical threshold, leading to selective vulnerability of cancer cells. Unlike traditional cytotoxic strategies that indiscriminately target dividing cells, this approach leverages the cancer cells’ own metabolic fragility to facilitate a therapeutic conversion, thereby potentially minimizing collateral damage to healthy tissues.

A particularly exciting aspect of this study is the translational potential of one of the enzyme inhibitors, which has already been granted orphan drug designation by the US Food and Drug Administration for a separate adult indication. This regulatory recognition not only underscores the compound’s safety profile but also accelerates its candidacy for clinical trials in pediatric neuroblastoma. The planned transition from preclinical models to human studies represents a critical next phase to evaluate safety, dosing parameters, and efficacy in the vulnerable pediatric population.

The repercussions of this research extend beyond neuroblastoma treatment. By exemplifying how targeting metabolic and redox vulnerabilities can induce differentiation in malignant cells, the study paves the way for broader applications in other cancers exhibiting similar dependencies. Furthermore, this enzymatic dual inhibition strategy might be combined synergistically with existing therapies, such as immunotherapy or low-dose chemotherapy, to enhance overall treatment outcomes while reducing long-term adverse effects.

Notwithstanding these promising findings, several challenges remain before clinical implementation can be realized. The complexity of neuroblastoma heterogeneity necessitates further studies to identify biomarkers that predict patient responsiveness to PRDX6 and GSTP1 inhibitors. Additionally, long-term effects of differentiated neurons within the tumor microenvironment need rigorous examination to ensure they do not revert to malignancy or adversely affect surrounding neural tissue. Comprehensive safety assessments are crucial given the delicate nature of pediatric neural systems.

Funding for this pivotal research was primarily provided by prominent Swedish organizations — the Swedish Research Council, the Swedish Cancer Society, the Swedish Childhood Cancer Fund, and the Radiumhemmet Research Funds — underscoring the national commitment to addressing childhood cancer. The researchers have also explicitly disclosed no conflicts of interest, enhancing the credibility and impartiality of the findings.

In summary, the innovative strategy of combining PRDX6 and GSTP1 inhibition to coerce neuroblastoma cells into differentiation marks a paradigm shift in pediatric oncology. By transforming malignant cells into harmless neurons, this approach may radically alter the therapeutic landscape, offering hope for improved survival rates and quality of life among afflicted children. As the scientific community eagerly anticipates forthcoming clinical trials, this study stands as a compelling testament to the power of molecular precision medicine in combating childhood cancers.

Subject of Research: Animals

Article Title: Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment

News Publication Date: 16 June 2025

Web References:
DOI link – 10.1073/pnas.2427211122

References:
Judit Liaño-Pons, Elisa Garde-Lapido, Fenja L. Fahrig, Merle Jäckering, Ye Yuan, Stina Andersson, Lea Schort, Maria Esteve, Sofie Mohlin, Oscar C. Bedoya-Reina, Marie Arsenian-Henriksson, “Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment,” Proceedings of the National Academy of Sciences, online 16 June 2025, doi: 10.1073/pnas.2427211122.

Keywords: Neuroblastoma, Cancer, Antioxidant Enzymes, PRDX6, GSTP1, Differentiation Therapy, Childhood Cancer, Oncology, Pediatrics, Cancer Cells, Pharmacology, Drug Research